|
| Press Releases |
|
 |
|
| Tuesday, October 3, 2023 |
|
|
HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101 |
| more info >> |
|
| Monday, August 28, 2023 |
|
|
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies |
| HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies more info >> |
|
|
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies |
| HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies more info >> |
|
| Monday, July 24, 2023 |
|
|
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
|
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the Taiwan Food and Drug Administration (TFDA) has approved its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
| Monday, April 17, 2023 |
|
|
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| more info >> |
|
|
HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies |
| HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
富士通、ＳＭＢＣ日興証券様のオンライン取引の不正アクセス対策として、生体認証サービスを導入
Feb 2, 2026 12:30: JST
|
|
|
Web-based tool makes it easier to design advanced materials
Feb 2, 2026 10:11: JST
|
|
|
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 2, 2026 10:00 JST
|
|
|
Web-based tool makes it easier to design advanced materials
Feb 2, 2026 08:00 HKT/SGT
|
|
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 18:00: JST
|
|
|
TCG.Zone Announces Strategic Pivot to High-Value Collectible Assets
Feb 1, 2026 17:00 HKT/SGT
|
|
|
Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre
Jan 31, 2026 21:00 HKT/SGT
|
|
|
Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre
Jan 31, 2026 21:00: JST
|
|
|
日清食品（香港）慈善基金连续第四年支持 香港教育大学精英运动员
Jan 31, 2026 07:21 HKT/SGT
|
|
|
REMSleep Receives Medicare PDAC Coding Approval for Complete DeltaWave Product Portfolio
Jan 31, 2026 02:40 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
Jan 30, 2026 22:30: JST
|
|
|
NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
Jan 30, 2026 21:30 HKT/SGT
|
|
|
SuperX Commences Production at First Global Supply Center
Jan 30, 2026 19:24 HKT/SGT
|
|
|
Quam Plus Financial Proudly Serves as Gold Sponsor, The 3rd Hong Kong Capital Markets Forum 2026 Successfully Concludes
Jan 30, 2026 19:18 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
